Personalized briefing
Top 5 discoveries · Oncology
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
Dear Maciej Harat — this week’s five most relevant discoveries, curated for your work in Oncology.
Key findings
Medicine · Thoracic Oncology
No. 1
This review critically examines the current perioperative chemoimmunotherapy standard for resectable non-small-cell lung cancer without driver alterations, highlighting the largely empirical nature of its development. The authors propose biomarker-driven strategies including de-escalation for patients achieving pathological complete response and escalation for those with early evidence of resistance. For the practicing oncologist, this framework provides a rational pathway to individualize treatment intensity and improve outcomes beyond a one-size-fits-all approach.
Novelty
80%
Rigor
90%
Significance
90%
Validity
85%
Clarity
95%
Medicine · Colorectal Oncology
No. 2
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
This prognostic study demonstrates that molecular residual disease defined by circulating tumor DNA after resection of colorectal liver metastases is strongly associated with survival outcomes. The results further indicate that patients with detectable ctDNA may derive a differential benefit from adjuvant chemotherapy, suggesting a role for ctDNA in treatment decision-making. For the oncologist managing colorectal cancer, this evidence supports incorporating ctDNA monitoring to identify high-risk patients who stand to gain the most from postoperative systemic therapy.
Novelty
85%
Rigor
95%
Significance
95%
Validity
90%
Clarity
90%
Medicine · Psycho-Oncology
No. 3
Serious mental illness and cancer: A call to action for equitable care
This review identifies severe disparities in cancer detection, treatment, and survival among patients with serious mental illness (SMI), who face a two-to-three-decade reduction in life expectancy. Key barriers include diagnostic overshadowing, fragmented care pathways, limited access to therapeutics, and underrepresentation in clinical trials. For the oncologist, the paper provides actionable recommendations such as collaborative care models and integrated psychiatric oncology services to close the outcome gap for this vulnerable population.
Novelty
90%
Rigor
85%
Significance
90%
Validity
85%
Clarity
90%
Medicine · Urologic Oncology
No. 4
Preventative Function-sparing Radical Prostatectomy: Experience in a Tertiary Referral Centre
This retrospective series reports outcomes of a preventative function-sparing radical prostatectomy approach performed at a high-volume tertiary centre, likely in men with elevated genetic risk. The technique prioritises preservation of continence and erectile function without compromising oncologic control. For the oncologist managing prostate cancer, these data provide real-world evidence on the safety and functional outcomes of prophylactic surgery in carefully selected high-risk patients.
Novelty
75%
Rigor
80%
Significance
85%
Validity
80%
Clarity
85%
Medicine · Cancer Epidemiology
No. 5
Stat Bite: Cancer risk factors in the US in 2024; obesity, BMI ≥ 30 in people over 20 years
The 2024 Behavioral Risk Factor Surveillance System data reveal that no US state had obesity prevalence below 25%, with ten states exceeding 35% of adults with BMI ≥30. Obesity is a well-established risk factor for at least 13 cancer types, linking population health trends directly to oncologic risk. For the oncologist, these statistics underscore the urgency of integrating weight management and lifestyle interventions into routine cancer prevention and survivorship care.
Novelty
70%
Rigor
75%
Significance
80%
Validity
80%
Clarity
85%
Advertisement
ScientificChina — verified Chinese lab & medical equipment suppliers, direct. Browse suppliers →
Your briefing is personalized based on your selected fields, keywords, and research interests.
